Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS

• Published in: Multiple sclerosis Vol. 24; no. 14; p. 1795
• Main Authors: Mills, Elizabeth A, Begay, Joel A, Fisher, Caitlyn, Mao-Draayer, Yang
• Format: Journal Article
• Language: English
• Published: England 01.12.2018
• Subjects: Progressive multiple sclerosis; clinical trial; neurodegeneration; immunomodulatory therapy
• ISSN: 1477-0970
• DOI: 10.1177/1352458518800800

Clinically effective immunomodulatory therapies have been developed for relapsing-remitting multiple sclerosis (RRMS), but they have generally not translated to a corresponding slowing of disability accumulation in progressive forms of multiple sclerosis (MS). Since disability is multifaceted, progressive patients are heterogeneous, and the drivers of disease progression are still unclear, it has been difficult to identify the most informative outcome measures for progressive trials. Historically, secondary outcome measures have focused on inflammatory measures, which contributed to the recent identification of immunomodulatory therapies benefiting younger patients with more inflammatory progressive MS. Meanwhile, agents capable of treating late-stage disease have remained elusive. Consequently, measures of neurodegeneration are becoming common. Here, we review completed clinical trials testing immunomodulatory therapies in primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and discuss the features contributing to trial design variability in relation to trial outcomes, and how efforts toward better patient stratification and inclusion of reliable progression markers could improve outcomes.